NextCure Stock Hits 52-Week Low Amid Sector Struggles NextCure Inc. (NASDAQ:NXTC) experienced a sharp decline, reaching a 52-week low of $0.66. The biotech firm faces ongoing challenges, including rapid cash burn and weak profit margins. Despite holding more cash than debt, investor confidence wanes due to the broader industry downturn and drug development hurdles.1